From Nasdaq: 2025-05-22 23:28:00

Astellas Pharma and Pfizer announce five-year follow-up results from Phase 3 ARCHES study showing XTANDI plus ADT reduces risk of death by 30% in men with mHSPC compared to placebo plus ADT. After 61.4 months, XTANDI plus ADT associated with 66% probability of survival at five years. XTANDI is first and only androgen receptor inhibitor to demonstrate overall survival benefit at five years for men with mHSPC. Data also show wide-ranging effects of treatment across various patient subgroups. XTANDI is approved in over 90 countries, including US, EU, and Japan.



Read more at Nasdaq: Astellas And Pfizer’s XTANDI Shows Long-Term Survival Benefits In Metastatic Prostate Cancer